Summary

Authorizes the United States to join and fund the Davos Alzheimer’s Collaborative (DAC) to help prevent, diagnose, and treat Alzheimer’s and other dementias worldwide, especially in low- and middle-income countries. It permits use of existing foreign assistance authorities for contributions, limits U.S. contributions to no more than 33% of DAC funding in FY2026–FY2030, allows a presidential designee to serve on DAC governance bodies, and requires regular reports to Congress on planned and actual U.S. participation and alignment with U.S. strategies.

• Authorizes U.S. participation and financial contributions to an international Alzheimer’s collaborative focused on prevention, diagnosis, and treatment.
• Permits use of existing foreign assistance authorities to fund contributions rather than creating a new appropriation.
• Caps U.S. government contributions at no more than 33% of total Collaborative funding during FY2026–FY2030 to ensure burden‑sharing.
• Allows the President to designate a federal employee to represent the U.S. on the Collaborative’s Advisory Council and potentially its Board, with coordination requirements across agencies.
• Requires an initial report within 180 days of enactment and annual reports to Congress on contributions, governance participation, and alignment with U.S. strategies.
• Specifically directs outreach to low- and middle-income countries and emphasizes development of diagnostics and treatments for diverse populations.
• Frames the policy around growing global burdens of dementia, disproportionate impacts on women and minority populations, and the need for international cooperation.